Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung Cancer

By HEOR Staff Writer

April 15, 2026

The FDA’s Priority Review of ifinatamab deruxtecan was recently announced, a potential first-in-class B7-H3 targeted therapy. The Biologics License Application for ifinatamab deruxtecan (I-DXd), a B7-H3 directed DXd antibody drug conjugate (ADC), has been accepted with a Prescription Drug User Fe...
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainability
In this update we examine how Novartis is embedding inclusive healthcare strategies into its core business by launching ambitious long-term Social Impact and Sustainability (SI&S) targets that reach to 2040. These targets integrate innovation, access to medicines, global health, environmental...
Advancing Access: Generic Dapagliflozin Approval Enhanced for Type 2 Diabetes Treatment

By João L. Carapinha

April 14, 2026

The U.S. Food and Drug Administration has issued the generic dapagliflozin approval, clearing the first generic versions of FARXIGA (dapagliflozin) tablets. This decision significantly improves affordability and access to an important SGLT2 inhibitor for adults with type 2 diabetes. ...